Citations

Clear

33 citation(s) found for "Sattar, H".

Pearls and Pitfalls of Adaptive Optics Ophthalmoscopy in Inherited Retinal Diseases
Ashourizadeh, Helia , Fakhri, Maryam , Hassanpour, Kiana , Masoudi, Ali Akbar , Jalali, Sattar, Roshandel, Danial , Chen, Fred K. , Masoudi, Ali, Jalali, Sattar

Mayo Clinic

Diagnostics | July 19, 2023 | Volume: 13 | Issue: 14 | Pages: 2413

10.3390/diagnostics13142413 | PMID 37510157 Get It

Adaptive optics (AO) retinal imaging enables individual photoreceptors to be visualized in the clinical setting. AO imaging can be a powerful clinical tool for detecting photoreceptor degeneration at a cellular level that might be overlooked through conventional structural assessments, such as spectral-domain optical coherence tomography (SD-OCT). Therefore, AO imaging has gained significant interest in the study of photoreceptor degeneration, one of the most common causes of inherited blindness. Growing evidence supports that AO imaging may be useful for diagnosing early-stage retinal dystrophy before it becomes apparent on fundus examination or conventional retinal imaging. In addition, serial AO imaging may detect structural disease progression in early-stage disease over a shorter period compared to SD-OCT. Although AO imaging is gaining popularity as a structural endpoint in clinical trials, the results should be interpreted with caution due to several pitfalls, including the lack of standardized imaging and image analysis protocols, frequent ocular comorbidities that affect image quality, and significant interindividual variation of normal values. Herein, we summarize the current state-of-the-art AO imaging and review its potential applications, limitations, and pitfalls in patients with inherited retinal diseases.
Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial
Osdoit, Marie , Symmans, W. Fraser , Ewing, Cheryl A. , Chen, Yunn‐Yi , Krings, Gregor , Zare, Somaye , Fadare, Oluwole , Lancaster, Rachael, Wei, Shi , Godellas, Constantine , Tang, Ping , Klein, Molly, Sahoo, Sunati , Carter, Jodi M. , Chen, Beiyun, Ahrendt, Gretchen , Tchou, Julia , Tousimis, Eleni A. , Zeck, Jay , Jaskowiak, Nora , Sattar, Husain, Naik, Arpana, Rosa, Marilin , Khazai, Laila , Rendi, Mara H. , Lang, Julie E. , Lu, Janice , Tawfik, Ossama , Asare, Smita , Symmans, W Fraser , Carter, Jodi , Yau, Christina , Boughey, Judy C. , Balassanian, Ronald , Wallace, Anne M. , Tuttle, Todd M. , Hieken, Tina J. , Feldman, Michael D. , Lee, Marie Catherine , Esserman, Laura J. , Mukhtar, Rita A.

Mayo Clinic

JAMA Surgery | September 7, 2022 | Volume: 157 | Issue: 11 | Pages: 1034

10.1001/jamasurg.2022.4118 | PMID 36069821 Get It

ImportancePathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in breast cancer strongly correlates with overall survival and has become the standard end point in neoadjuvant trials. However, there is controversy regarding whether the definition of pCR should exclude or permit the presence of residual ductal carcinoma in situ (DCIS).ObjectiveTo examine the association of residual DCIS in surgical specimens after neoadjuvant chemotherapy for breast cancer with survival end points to inform standards for the assessment of pathologic complete response.Design, Setting, and ParticipantsThe study team analyzed the association of residual DCIS after NAC with 3-year event-free survival (EFS), distant recurrence-free survival (DRFS), and local-regional recurrence (LRR) in the I-SPY2 trial, an adaptive neoadjuvant platform trial for patients with breast cancer at high risk of recurrence. This is a retrospective analysis of clinical specimens and data from the ongoing I-SPY2 adaptive platform trial of novel therapeutics on a background of standard of care for early breast cancer. I-SPY2 participants are adult women diagnosed with stage II/III breast cancer at high risk of recurrence.InterventionsParticipants were randomized to receive taxane and anthracycline-based neoadjuvant therapy with or without 1 of 10 investigational agents, followed by definitive surgery.Main Outcomes and MeasuresThe presence of DCIS and EFS, DRFS, and LRR.ResultsThe study team identified 933 I-SPY2 participants (aged 24 to 77 years) with complete pathology and follow-up data. Median follow-up time was 3.9 years; 337 participants (36%) had no residual invasive disease (residual cancer burden 0, or pCR). Of the 337 participants with pCR, 70 (21%) had residual DCIS, which varied significantly by tumor-receptor subtype; residual DCIS was present in 8.5% of triple negative tumors, 15.6% of hormone-receptor positive tumors, and 36.6% of ERBB2-positive tumors. Among those participants with pCR, there was no significant difference in EFS, DRFS, or LRR based on presence or absence of residual DCIS.Conclusions and RelevanceThe analysis supports the definition of pCR as the absence of invasive disease after NAC regardless of the presence or absence of DCIS.Trial RegistrationClinicalTrials.gov Identifier NCT01042379.
Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation
López-Jiménez, Francisco , Almahmeed, Wael , Bays, Harold , Cuevas, Ada , Angelantonio, Emanuele Di , Roux, Carel W. le , Sattar, Naveed , Sun, Marie Chan , Wittert, Gary , Pinto, Fausto J. , Wilding, John , Di Angelantonio, Emanuele , le Roux, Carel W , Wilding, John P H , Lopez-Jimenez, Francisco , Sattar, Naveed

Mayo Clinic

European Journal of Preventive Cardiology | August 24, 2022 | Volume: 29 | Issue: 17 | Pages: 2218-2237

10.1093/eurjpc/zwac187 | PMID 36007112 Get It

Abstract The ongoing obesity epidemic represents a global public health crisis that contributes to poor health outcomes, reduced quality of life, and >2.8 million deaths each year. Obesity is relapsing, progressive, and heterogeneous. It is considered a chronic disease by the World Obesity Federation (WOF) and a chronic condition by the World Heart Federation (WHF). People living with overweight/obesity are at greater risk for cardiovascular (CV) morbidity and mortality. Increased adiposity (body fat), particularly visceral/abdominal fat, is linked to CV risk and CV disease (CVD) via multiple direct and indirect pathophysiological mechanisms. The development of CVD is driven, in part, by obesity-related metabolic, endocrinologic, immunologic, structural, humoral, haemodynamic, and functional alterations. The complex multifaceted nature of these mechanisms can be challenging to understand and address in clinical practice. People living with obesity and CVD often have concurrent chronic physical or psychological disorders (multimorbidity) requiring multidisciplinary care pathways and polypharmacy. Evidence indicates that intentional weight loss (particularly when substantial) lowers CVD risk among people with overweight/obesity. Long-term weight loss and maintenance require ongoing commitment from both the individual and those responsible for their care. This position paper, developed by the WOF and the WHF, aims to improve understanding of the direct and indirect links between overweight/obesity and CVD, the key controversies in this area and evidence relating to cardiometabolic outcomes with available weight management options. Finally, an action plan for clinicians provides recommendations to help in identifying and addressing the risks of obesity-related CVD (recognizing resource and support variances between countries).
Analysis of somatic mutations in 131 human brains reveals aging-associated hypermutability
Bae, Taejeong , Fasching, Liana , Wang, Yifan , Shin, Joo Heon , Šuvakov, Milovan , Jang, Yeongjun , Norton, Scott , Dias, Caroline , Mariani, Jessica , Jourdon, Alexandre , Wu, Feinan , Panda, Arijit , Pattni, Reenal , Chahine, Yasmine, Yeh, Rebecca C., Roberts, Rosalinda C. , Hüttner, Anita , Straub, Richard E. , Walsh, Christopher A. , Network§, Brain Somatic Mosaicism, Urban, Alexander E. , Weinberger, Daniel R. , Vaccarino, Flora M. , Abyzov, Alexej , Šestan, Nenad , Moran, John V. , Gleeson, Joseph G. , Mathern, Gary W. , Courchesne, Eric, Chess, Andrew , Bizzotto, Sara , D’Gama, Alissa M. , Hill, Robert , Kim, Sonia , Miller, Michael , Borges-Monroy, Rebeca , Bohrson, Craig L. , Galor, Alon , Kwon, Min‐Seok , Luquette, Joe, Sherman, Maxwell A. , Rosenbluh, Chaggai , Cho, Sean, Thorpe, Jeremy , McConnell, Michael J. , Narurkar, Rujuta, Paquola, Apuã C.M. , Shin, Jooheon, Molitor, Cindy, Peters, Mette A. , Linker, Sara B. , Reed, Patrick , Wang, Meiyan , Zhou, Bo , Amero, Aitor Serres, Lobón, Irene , Moruno, Manuel Solis, Pérez, Raquel García, Povolotskaya, Inna , Soriano, Eduardo , Antaki, Danny , Averbuj, Dan, Ball, Laurel, Yang, Xiaoxu , Chung, Changuk , Emery, Sarah B., Flasch, Diane A. , Sun, Chen , Zhao, Xuefang , Zhou, Weichen , Frisbie, Trenton J., Cherskov, Adriana , Pochareddy, Sirisha , Kleinman, Joel E , Hyde, Thomas M , Straub, Richard E , Walsh, Christopher A , Urban, Alexander E , Leckman, James F , Weinberger, Daniel R , Vaccarino, Flora M , Abyzov, Alexej , Shin, Joo Heon , Zhou, Bo , Šuvakov, Milovan , Bae, Taejeong , Wang, Yifan , Jang, Yeongjun , Network§, Brain Somatic Mosaicism, Leckman, James F. , Park, Peter J. , Gage, Fred H , Gleeson, Joseph G. , Courchesne, Eric, Roy, Subhojit , Akbarian, Schahram , Coulter, Michael E. , Ganz, Javier , Hill, Robert, Huang, August Yue , Khoshkhoo, Sattar , Lee, Alice , Lodato, Michael A. , Maury, Eduardo A. , Rodin, Rachel E. , Zhou, Zinan , Chu, Chong , Cortés‐Ciriano, Isidro , Dou, Yanmei , Gulhan, D. , Viswanadham, Vinay , Jones, Attila , Langmead, Ben , Erwin, Jennifer A. , Jaffe, Andrew E. , Zhu, Xiaowei , Juan, David , Marquès‐Bonet, Tomàs , Breuss, Martin W. , Kidd, Jeffrey M. , Kopera, Huira C. , Kwan, Kenneth Y , Mills, Ryan E. , Moldovan, John B. , Scuderi, Soraya

Mayo Clinic

Science | July 28, 2022 | Volume: 377 | Issue: 6605 | Pages: 511-517

10.1126/science.abm6222 | PMID 35901164 Get It

We analyzed 131 human brains (44 neurotypical, 19 with Tourette syndrome, 9 with schizophrenia, and 59 with autism) for somatic mutations after whole genome sequencing to a depth of more than 200×. Typically, brains had 20 to 60 detectable single-nucleotide mutations, but ~6% of brains harbored hundreds of somatic mutations. Hypermutability was associated with age and damaging mutations in genes implicated in cancers and, in some brains, reflected in vivo clonal expansions. Somatic duplications, likely arising during development, were found in ~5% of normal and diseased brains, reflecting background mutagenesis. Brains with autism were associated with mutations creating putative transcription factor binding motifs in enhancer-like regions in the developing brain. The top-ranked affected motifs corresponded to MEIS (myeloid ectopic viral integration site) transcription factors, suggesting a potential link between their involvement in gene regulation and autism.
Abstract 172: Disparities In Pcsk9 Inhibitor Initiation Among Patients With Peripheral Arterial Disease Or Cerebrovascular Disease: A Cohort Study Of 500,000 Patients With Atherosclerotic Vascular Disease.
Laforest, Sherry K, Bal, Simer, Elgudin, Yakov , Deo, Salil V. , McAllister, David , Altarabsheh, Salah E. , Sattar, Naveed , Pell, Jill P.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | May 12, 2022 | Volume: 15 | Issue: Suppl_1 | Pages: No page available

10.1161/circoutcomes.15.suppl_1.172 Get It

Background: Effective lipid lowering therapy reduces deaths due to atherosclerotic vascular disease (ASCVD). Proprotein convertase subtilsin/kexin type 9 inhibitor (PCSK9i) drugs have emerged as effective add-on therapy to lower low-density lipoprotein (LDL) levels. Although the use of PCSK9i is limited by cost, PCSK9i use in a low-cost healthcare system [Veteran Health Affairs (VHA)] is unknown. Methods: We queried a cohort of US Veterans with coronary artery disease (CAD), PAD or CeVD receiving outpatient care (January 2016 – December 2019) at 124 VHA medical centers to evaluate the initiation of PCSK9i. We fit a mixed effects logistic regression model [with results presented as odds ratio (OR)] to evaluate the association of social deprivation (assessed by median household income and community deprivation index), the patient’s primary diagnosis and VHA medical center enrollment with PCSK9i initiation. Findings: From 519,566 patients (median age 74 years), 337,766 (65%), 79,926 (15%) and 101,874 (20%) had CAD, PAD and CeVD. Among 2,115/519,566 (0.4%) initiated with PCSK9i therapy, 84.3% had CAD, while only 7.2% and 8.5% had PAD and CeVD respectively. PCSK9i initiation was lower in those earning $40,000 - $80,000 [OR 1.13 (1.01 – 1.27)] or > $80,000 [OR 1.41 (1.14 – 1.75)]. Even moderate community deprivation [OR 0.87 (0.77 – 0.97)] was associated with lower PCSK9i therapy. Compared to CAD patients, PAD [OR 0.50 (0.35 – 0.70)] and CeVD [OR 0.23 (0.15 – 0.37)] were less likely to receive PCSK9i. Interpretation: Despite low co-pay, PCSK9i initiation rates among US veterans, nationwide, is very low. PAD and CeVD patients are much less likely to receive PCSK9i therapy. Household income and community deprivation influence PCSK9i use.
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer
Symmans, W. Fraser , Chen, Yunn-Yi, Klein, Molly, Nanda, Rita , Parker, Barbara A. , Datnow, Brian, Krings, Gregor , Wei, Shi , Duan, Xiuzhen, Chen, Beiyun, Sattar, Husain, Khazai, Laila , Zeck, Jay , Sams, Sharon B. , Mhawech‐Fauceglia, Paulette , Rendi, Mara H. , Sahoo, Sunati , Ocal, Idris Tolgay, Fan, Fang, LeBeau, Lauren, Vinh, Tuyethoa N., Troxell, Megan L. , Chien, A. Jo , Forero‐Torres, Andres , Ellis, Erin D. , Albain, Kathy S. , Liu, Minetta C. , Haley, Barbara , Clark, Amy S. , Kemmer, Kathleen, Lang, Julie E. , Edmiston, Kirsten K., Viscusi, Rebecca K., Northfelt, Donald W. , Khan, Qamar J. , Leyland‐Jones, Brian , Venters, Sara J., Shad, Sonal , Matthews, Jeffrey B. , Asare, Smita , Buxton, Meredith , Asare, Adam L. , Schwab, Richard B. , Veer, Laura van ‘t , Perlmutter, Jane , Yee, Douglas , Berry, Donald A. , Esserman, Laura J. , Symmans, W Fraser , Esserman, Laura J , Asare, Adam L , Yee, Douglas , Yau, Christina , Chen, Yunn‐Yi , Balassanian, Ronald , Pusztai, Lajos , Feldman, Michael D. , Wallace, Anne M. , Murthy, Rashmi Krishna , Boughey, Judy C. , Elias, Anthony , Isaacs, Claudine , Han, Hyo S , Matthews, Jeffrey B., Rugo, Hope S. , Helsten, Teresa L. , Hylton, Nola M. , Veer, Laura J. van’t , DeMichele, Angela

Mayo Clinic

JAMA Oncology | September 16, 2021 | Volume: 7 | Issue: 11 | Pages: 1654

10.1001/jamaoncol.2021.3690 | PMID 34529000 Get It

Ramadan fasting: recommendations for patients with cardiovascular disease
Akhtar, Abid Mohammed , Ghouri, Nazim , Chahal, C. Anwar A. , Patel, Riyaz , Sattar, Naveed , Waqar, Salman , Khanji, Mohammed Y , Sattar, Naveed , Khanji, Mohammed Yunus , Chahal, Choudhary Anwar A , Ricci, Fabrizio

Mayo Clinic

Heart | May 14, 2021 | Volume: 108 | Issue: 4 | Pages: 258-265

10.1136/heartjnl-2021-319273 | PMID 33990414 Get It

Ramadan fasting is observed by most of the 1.8 billion Muslims around the world. It lasts for 1 month per the lunar calendar year and is the abstention from any food and drink from dawn to sunset. While recommendations on ‘safe’ fasting exist for patients with some chronic conditions, such as diabetes mellitus, guidance for patients with cardiovascular disease is lacking. We reviewed the literature to help healthcare professionals educate, discuss and manage patients with cardiovascular conditions, who are considering fasting. Studies on the safety of Ramadan fasting in patients with cardiac disease are sparse, observational, of small sample size and have short follow-up. Using expert consensus and a recognised framework, we risk stratified patients into ‘low or moderate risk’, for example, stable angina or non-severe heart failure; ‘high risk’, for example, poorly controlled arrhythmias or recent myocardial infarction; and ‘very high risk’, for example, advanced heart failure. The ‘low-moderate risk’ group may fast, provided their medications and clinical conditions allow. The ‘high’ or ‘very high risk’ groups should not fast and may consider safe alternatives such as non-consecutive fasts or fasting shorter days, for example, during winter. All patients who are fasting should be educated before Ramadan on their risk and management (including the risk of dehydration, fluid overload and terminating the fast if they become unwell) and reviewed after Ramadan to reassess their risk status and condition. Further studies to clarify the benefits and risks of fasting on the cardiovascular system in patients with different cardiovascular conditions should help refine these recommendations.
Outcomes of Transradial Versus Transfemoral Access of Percutaneous Coronary Intervention in STEMI: Systematic Review and Updated Meta-analysis
Sattar, Yasar , Majmundar, Monil , Ullah, Waqas , Mamtani, Sahil , Robinson, Sam, Dhamrah, Umaima , Al‐Khadra, Yasser , Pacha, Homam Moussa , Darmoch, Fahed , Soud, Mohamad , Hakim, Zaher, Kaul, Prashant , Ijioma, Nkechinyere , Panchal, Ankur , Soud, Mohamad , Alraies, M Chadi , Sattar, Yasar , Ijioma, Nkechi , Kumar, Ashish , Zghouzi, Mohamed , Mir, Tanveer , Bagur, Rodrigo , Shroff, Adhir

Mayo Clinic

Expert Review of Cardiovascular Therapy | April 26, 2021 | Volume: 19 | Issue: 5 | Pages: 433-444

10.1080/14779072.2021.1915768 | PMID 33896335 Get It

Temporal trends in utilization and outcomes of transcatheter aortic valve replacement in different races: an analysis of the national inpatient sample
Ullah, Waqas , Al‐Khadra, Yasser , Darmoch, Fahed , Pacha, Homam Moussa , Ijioma, Nketchi, Mohamed, Mohamed O. , Asfour, Abedelrahim I., Rizik, David G. , Zehr, Kenton J., Mamas, Mamas A. , Ijioma, Nkechinyere , Mamas, Mamas , Mohamed, Mohamed O , Ijioma, Nkechi , Mir, Tanveer , Sattar, Yasar , Kwok, Chun Shing , Kapadia, Samir , Alraies, M Chadi

Mayo Clinic

Journal of Cardiovascular Medicine | March 2, 2021 | Volume: 22 | Issue: 7 | Pages: 586-593

10.2459/jcm.0000000000001172 | PMID 34076606 Get It

Aim We sought to determine the racial and ethnical disparities in the delivery of TAVR and to evaluate the in-hospital outcomes and utilization of TAVR stratified by patient ethnicity. Method Using a national inpatient sample database between 2011 and 2015, we identified all adult patients who had TAVR. Races were identified and white race was set as control. Multiple logistic regression analysis was performed for the primary outcome of in-hospital mortality. Results Out of 58 174 patients who underwent TAVR, 50 809 (87.3%) were white, 2327 (4.0%) were black, 2311 (4.0%) were Hispanic, 640 (1.1%) Asian, 105 (0.2%) Native American and 1982 (3.4%) of other ethnicities. We found a statistically significant linear uptrend in the utilization of TAVR in patients of all races between the years 2011 and 2015. White, black, Hispanic and Native American patients had a downward linear trend for mortality during the studied years ( P ≤ 0.005 for all). Black patients had lower in-hospital mortality [2.8 vs. 3.6%, odds ratio (OR) = 0.62; 95% confidence interval (CI) 0.44, 0.81 P < 0.001] compared with white patients, whereas Hispanic patients and Native Americans had higher in-hospital mortality compared with white patients (4.5% OR 1.26; 95% CI 1.01, 1.56 P = 0.041), (9.5% OR 4.44; 95% CI 2.25, 8.77 P < 0.001), respectively. Conclusion Overall, TAVR utilization is associated with lower mortality. There is a rising trend in utilization of TAVR in the black population with a significantly favorable mortality trend compared with the white population.